Abstract Number: 1214 • ACR Convergence 2020
Association Between Changes in C-reactive Protein at Week 12 and Patient-Reported Outcomes at Week 24 with Sarilumab Therapy Across Three Pivotal Phase 3 Studies
Background/Purpose: Evaluation of response to RA therapy at 12 weeks after initiation is recommended in treatment guidelines. CRP response after 12 weeks of therapy may…Abstract Number: 1232 • ACR Convergence 2020
Association of Low Hemoglobin with Efficacy and Patient-reported Outcomes in Three Phase III Studies of Sarilumab (TARGET, MOBILITY and MONARCH)
Background/Purpose: Anemia is a common comorbidity in patients (pts) with RA, and changes in hemoglobin (Hb) levels are associated with changes in inflammatory disease activity. Since…Abstract Number: 1358 • ACR Convergence 2020
Certolizumab Pegol Efficacy in Patients with Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status
Background/Purpose: This post-hoc analysis from the phase 3 C-axSpAnd study aimed to evaluate whether the response to certolizumab pegol (CZP) in non-radiographic axial spondyloarthritis (nr-axSpA)…Abstract Number: 1366 • ACR Convergence 2020
Secukinumab Improved Signs and Symptoms in Patients with Non-radiographic Axial Spondyloarthritis: Results from a Randomized Controlled Phase III Study Stratified by Baseline Objective Signs of Inflammation
Background/Purpose: Active non-radiographic axial spondyloarthritis (nr-axSpA) is often determined on the basis of objective signs of inflammation (elevated C-reactive protein [CRP] and/or evidence of sacroiliitis…Abstract Number: 1891 • ACR Convergence 2020
Impact of Utilising Smart Phone Application in Ankylosing Spondylitis: SMART- as Study
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the axial skeleton and characterized by inflammatory back pain, leading to decreased mobility,…Abstract Number: 1904 • ACR Convergence 2020
Clinical Features of Patients with Active Ankylosing Spondylitis Who Did Not Respond to Adalimumab but Responded to Ixekizumab: A Post-hoc Analysis
Background/Purpose: Biologic therapy is recommended in patients with active ankylosing spondylitis (AS) despite adequate trial of NSAIDs. Biologic treatment in AS are currently limited to…Abstract Number: 2006 • ACR Convergence 2020
Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data
Background/Purpose: Despite the existence of guidelines for DMARD treatment of RA, a more individualized approach to treatment is needed to maximize efficacy while minimizing risk…Abstract Number: 0034 • ACR Convergence 2020
Gene Expression Signatures in C-Reactive Protein High and Low Rheumatoid Arthritis
Background/Purpose: Transcriptome profiling has expanded our ability to identify biomarkers and therapeutic targets and better understand disease progression in a wide variety of conditions. Serum…Abstract Number: 0097 • ACR Convergence 2020
Does Testing for SAA Is More Beneficial Than CRP for the Follow-up of Patients with FMF?
Background/Purpose: In order to follow subclinical inflammation and adjust the therapy for an optimal disease control, clinicians seek for readily accessible, affordable and reproducible markers.…Abstract Number: 0404 • ACR Convergence 2020
Isolated Aortitis: Single Centre Experience of Clinical Spectrum and Management
Background/Purpose: Aortitis was previously regarded as a rare form of large vessel vasculitis (LVV), but is now increasingly being recognised. It may occur in the…Abstract Number: 0626 • ACR Convergence 2020
Early Rise in CRP Is Associated with Progression to Respiratory Failure and Intubation in COVID-19 Patients
Background/Purpose: During the course of hospitalization, it is often unclear which COVID-19 patients will progress from non-critical to critical illness. Timely identification of these patients…Abstract Number: 0827 • ACR Convergence 2020
Comparative Clinical Efficacy of Sarilumab versus Upadacitinib over 12 Weeks: Matching-Adjusted Indirect Comparison Analysis
Background/Purpose: Sarilumab, an IL-6 receptor inhibitor, and upadacitinib, a Janus kinase (JAK) 1 inhibitor, are both approved for the treatment of patients with moderately to…Abstract Number: 0828 • ACR Convergence 2020
Clinical and Functional Response to Tofacitinib in Patients with Rheumatoid Arthritis: Probability Plot Analysis of Results from a Phase 3b/4 Methotrexate Withdrawal Study
Background/Purpose: ORAL Shift (NCT02831855) was a 48-week Phase 3b/4 study, which demonstrated sustained efficacy/safety of tofacitinib modified release 11 mg once daily (QD) following MTX…Abstract Number: 340 • 2019 ACR/ARP Annual Meeting
Increased Physical Activity in Gout Patients Correlates with Better Prognosis, Decreased Pain, and Suppressed C-Reactive Protein Levels
Background/Purpose: Regular exercise programs were previously thought to be inappropriate in patients with rheumatic diseases because of the potential to exacerbate inflammation. However, while recent paradigm-shifting…Abstract Number: 1398 • 2019 ACR/ARP Annual Meeting
Sarilumab and Tocilizumab Receptor Occupancy (RO), and Effects on C-Reactive Protein (CRP) Levels, in Patients with Rheumatoid Arthritis (RA)
Background/Purpose: The in vitro binding affinity of sarilumab (KD 61.9 pM) for the human interleukin-6 receptor (IL-6R) is 15–22-fold higher than that of tocilizumab. This…
- 1
- 2
- 3
- …
- 5
- Next Page »